Writing in GI & Hepatology News’ Practice Management toolbox, a group of GIs note that over the last several years, payer policies that dictate and restrict treatments for patients with inflammatory bowel diseases (IBD) have proliferated.
According to a recent survey of AGA members, an overwhelming majority reported that payer policies of prior authorization (PA), step therapy and non-medical switching have had a negative impact on patients’ access to clinically appropriate treatments. Reducing the burdens of these policies is a major priority for AGA advocacy.